骨髓增生异常肿瘤免疫相关治疗的研究现状  

Research status on immunotherapy of myelodysplastic neoplasms

作　　者：骆成荣 史仲珣 沈文怡[1] Luo Chengrong;Shi Zhongxun;Shen Wenyi(Department of Hematology,First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital,Nanjing 210029,Jiangsu Province,China)

机构地区：[1]南京医科大学第一附属医院江苏省人民医院血液科,南京210029

出　　处：《国际输血及血液学杂志》2023年第3期192-199,共8页International Journal of Blood Transfusion and Hematology

基　　金：国家自然科学基金(82200151);江苏省"六大人才高峰"高层次人才项目(WSN-026)。

摘　　要：骨髓增生异常肿瘤(MDS)是一组起源于造血干细胞(HSC)的恶性克隆性疾病,现有治疗策略下MDS患者的总体预后不容乐观,异基因造血干细胞移植(allo-HSCT)目前仍是治愈MDS的唯一选择。随着对MDS发病机制研究的不断深入,有证据表明免疫失调可能是MDS发生、发展的关键驱动因素,通过调节自身免疫抑制或清除肿瘤细胞的免疫相关疗法也成为MDS治疗领域的研究热点,多种免疫相关新药已在临床试验中初见成效。笔者现通过免疫调节剂(IMiD)、免疫检查点抑制剂(ICI)、肿瘤靶向抗体药物、靶向免疫信号通路药物、细胞治疗及肿瘤疫苗等方面对MDS免疫相关治疗中的机制及其研究现状进行阐述。Myelodysplastic neoplasms(MDS)are a group of malignant clonal diseases originating from hematopoietic stem cells(HSC).Under the current therapeutic strategies,the overall prognosis of patients with MDS is poor.Allogeneic hematopoietic stem cell transplantation(allo-HSCT)remains the only option to cure MDS potentially.With the continuous deepening of research on the pathogenesis of MDS,there is a evidence that immune dysfunction may be a key driving factor for the occurrence and development of MDS.Immunotherapy that suppresses or clears tumor cells by regulating autoimmunity has also become a research hotspot in the MDS treatment,and multiple immune related new drugs have achieved promising results in clinical trials.This article describes the specific mechanism and research status of MDS immune related therapy through aspects of immunomodulatory drugs(IMiD),immune checkpoint inhibitors(ICI),tumor targeted antibody drugs,targeted immune signal pathway drugs,cell therapy and cancer vaccine.

关 键 词：骨髓增生异常肿瘤 免疫疗法 免疫调节 免疫抑制法 分子靶向治疗 

分 类 号：R733.3[医药卫生—肿瘤]